Michael Hennig
leadXpro AG, Switzerland
Structure-based drug discovery enabled for membrane protein targets
Biography
Michael Hennig
studied Physics and Biochemistry, received the Ph.D. in structural biology at
EMBL Hamburg, and the Charité, Humboldt University Berlin, Germany. It followed
two years postdoc work at the Biozentrum, University of Basel, Switzerland. He
is author of more than 80 scientific peer reviewed paper and, since 2011, guest
professor in structural biology at the University of Basel. He worked 20 years
in pharmaceutical industry at Roche, Basel, Switzerland in various positions
and finally Global Head and Principle Leader of discovery technologies with
responsibility for structure-based drug discovery, protein science, assay development
and HTS, Roche corporate compound library, stem cell platform and analytical
physical methods. In 2015, he co-founded leadXpro, a corporation dedicated to
structure-based drug discovery for membrane protein targets (GPCR’s,
Ion-channels, Transporter) and utilizing most advanced technologies such as the
X-ray free electron laser (at PSI, SwissFEL) and cryo-electron microscopy (at
University of Basel, cryo-EM).